187 related articles for article (PubMed ID: 9416933)
1. Effect of extended-release isosorbide mononitrate one hour after dosing in patients with stable angina pectoris. IMDUR Study Group.
Glasser SP
Am J Cardiol; 1997 Dec; 80(12):1546-50. PubMed ID: 9416933
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of extended-release isosorbide mononitrate for stable effort angina pectoris.
Chrysant SG; Glasser SP; Bittar N; Shahidi FE; Danisa K; Ibrahim R; Watts LE; Garutti RJ; Ferraresi R; Casareto R
Am J Cardiol; 1993 Dec; 72(17):1249-56. PubMed ID: 8256699
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of controlled-release isosorbide-5-mononitrate in Japanese patients with stable effort angina pectoris.
Shimada K; Sunayama S; Nakazato K; Satoh H; Kusama Y; Kawakubo K; Daida H
Int Heart J; 2006 Sep; 47(5):695-705. PubMed ID: 17106140
[TBL] [Abstract][Full Text] [Related]
4. Anti-ischemic and anti-anginal effects of controlled-release and conventional isosorbide-5-mononitrate in stable angina pectoris.
Chen YH; Ding PY; Wang SP
Zhonghua Yi Xue Za Zhi (Taipei); 1998 Oct; 61(10):577-83. PubMed ID: 9830234
[TBL] [Abstract][Full Text] [Related]
5. Once- versus twice-daily administration of controlled-release isosorbide-5-mononitrate 60 mg in the treatment of stable angina pectoris. A randomized, double-blind, cross-over study. The Swedish Multicentre Group.
Nordlander R; Walter M
Eur Heart J; 1994 Jan; 15(1):108-13. PubMed ID: 8174569
[TBL] [Abstract][Full Text] [Related]
6. Sustained effect of and lack of development of tolerance to controlled-release isosorbide-5-mononitrate in chronic stable angina pectoris.
Wisenberg G; Roks C; Nichol P; Goddard MD
Am J Cardiol; 1989 Sep; 64(10):569-76. PubMed ID: 2782247
[TBL] [Abstract][Full Text] [Related]
7. Lack of pharmacologic tolerance and rebound angina pectoris during twice-daily therapy with isosorbide-5-mononitrate.
Thadani U; Maranda CR; Amsterdam E; Spaccavento L; Friedman RG; Chernoff R; Zellner S; Gorwit J; Hinderaker PH
Ann Intern Med; 1994 Mar; 120(5):353-9. PubMed ID: 8093132
[TBL] [Abstract][Full Text] [Related]
8. Nitrate-induced headache in patients with stable angina pectoris: beneficial effect of starting on a low dosage. 5-ISMN headache study group.
Cleophas TJ; Niemeyer MC; van der Wall EE; van der Meulen J
Angiology; 1996 Jul; 47(7):679-85. PubMed ID: 8686962
[TBL] [Abstract][Full Text] [Related]
9. A comparison of nifedipine once daily (Adalat LA), isosorbide mononitrate once daily, and isosorbide dinitrate twice daily in patients with chronic stable angina.
Walker JM; Curry PV; Bailey AE; Steare SE
Int J Cardiol; 1996 Feb; 53(2):117-26. PubMed ID: 8682597
[TBL] [Abstract][Full Text] [Related]
10. Comparison of 50-mg and 100-mg sustained-release isosorbide mononitrate in the treatment of stable angina pectoris: effects on quality-of-life indices. Dutch Mononitrate Quality of Life (DUMQOL) Study Group.
Zwinderman AH; Cleophas TJ; van der Sluijs H; Niemeyer MG; Buunk BP; van der Wall EE
Angiology; 1999 Dec; 50(12):963-9. PubMed ID: 10609762
[TBL] [Abstract][Full Text] [Related]
11. Eccentric dosing with isosorbide-5-mononitrate in angina pectoris.
Parker JO
Am J Cardiol; 1993 Oct; 72(12):871-6. PubMed ID: 8213541
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of controlled-release isosorbide-5-mononitrate as adjunctive treatment to beta-blocking agents in patients with stable angina pectoris.
Svendsen JH; Aldershvile J; Abildgaard U; Amtorp O
J Cardiovasc Pharmacol; 1989 Sep; 14(3):358-63. PubMed ID: 2476613
[TBL] [Abstract][Full Text] [Related]
13. The effect of isosorbide-5-mononitrate (5-ISMN) Durules on exercise tolerance in patients with exertional angina pectoris. A placebo controlled study.
Nyberg G; Carlens P; Lindström E; Lundman T; Nordlander R; Rehnqvist N; Ulvenstam G; Aberg A; Aström H
Eur Heart J; 1986 Oct; 7(10):835-42. PubMed ID: 3539613
[TBL] [Abstract][Full Text] [Related]
14. Comparison between felodipine and isosorbide mononitrate as adjunct to beta blockade in patients > 65 years of age with angina pectoris.
de Vries RJ; Dunselman PH; van Veldhuisen DJ; van den Heuvel AF; Wielenga RP; Lie KI
Am J Cardiol; 1994 Dec; 74(12):1201-6. PubMed ID: 7977090
[TBL] [Abstract][Full Text] [Related]
15. Isosorbide mononitrate 30% immediate-release 70% sustained-release formulation: a review. DUMQOL (DUtch Mononitrate Quality of Life) Study Group.
Cleophas TJ; Niemeyer MG; Zwinderman AH; van der Wall EE
Angiology; 2000 Aug; 51(8):631-8. PubMed ID: 10959515
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the antianginal effect of isosorbide-5-mononitrate in patients with chronic stable angina pectoris.
Yasky J; Ontanilla E; Koch JE
Cardiology; 1991; 79 Suppl 2():27-30. PubMed ID: 1760826
[TBL] [Abstract][Full Text] [Related]
17. [Isosorbide-5-mononitrate in angina pectoris: its efficacy and absence of tolerance and rebound with an eccentric type of administration].
Schneeweiss A; Reisin L; Marmor A; Caspi A
Cardiology; 1994; 84 Suppl 1():4-12. PubMed ID: 8087823
[TBL] [Abstract][Full Text] [Related]
18. N-acetylcysteine modifies the acute effects of isosorbide-5-mononitrate in angina pectoris patients evaluated by exercise testing.
Svendsen JH; Klarlund K; Aldershvile J; Waldorff S
J Cardiovasc Pharmacol; 1989 Feb; 13(2):320-3. PubMed ID: 2468964
[TBL] [Abstract][Full Text] [Related]
19. Isosorbide 5-mononitrate: a review of a sustained-release formulation (Imdur) in stable angina pectoris.
Gunasekara NS; Noble S
Drugs; 1999 Feb; 57(2):261-77. PubMed ID: 10188765
[TBL] [Abstract][Full Text] [Related]
20. Controlled release isosorbide-5-mononitrate in angina pectoris: a comparison with standard formulation isosorbide dinitrate.
Parker JO
Can J Cardiol; 1991 Apr; 7(3):125-30. PubMed ID: 2044014
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
